FindTrial
Sign In

A randomized study on the use of thalidomide administered either in a continually route or in cycles in association with high dose dexamethasone in patients with refractory or relapsed multiple myeloma.

A randomized study on the use of thalidomide administered either in a continually route or in cycles in association with high dose dexamethasone in patients with refractory or relapsed multiple myeloma.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000292-17-IT
Enrollment
Unknown
Registered
2005-09-07
Start date
2005-03-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma. MedDRA version: 6.1 Level: PT Classification code 10028228

Interventions

Trade Name: Thalidomide Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Thalidomide Concentration unit: mg milligram(s) Concentration type: equal Concentration numbe

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026